Chronic pain is the strongest single indication in the cannabis-medicine literature. The 2017 National Academies of Sciences report concluded there is "conclusive or substantial evidence" that cannabis is effective for chronic pain in adults, which is the strongest evidence finding NASEM issued for any of the conditions they reviewed. The Whiting 2015 JAMA meta-analysis of 28 trials found roughly 30 percent pain reduction with cannabinoid treatment. The 2025 AHRQ Living Systematic Review continues to find moderate-strength evidence. This is a different evidence state than the sleep, anxiety, or mood literatures, which are still building. The chronic pain evidence base is ready for clinical adoption, and in many ways the clinical adoption has lagged the evidence rather than the other way around.
The complication is that chronic pain is not one condition. It is at least four distinct mechanisms wearing one diagnostic label. Tissue damage produces nociceptive pain. Nerve damage or dysfunction produces neuropathic pain. Central nervous system sensitization without a clear peripheral driver produces nociplastic pain. And many real chronic pain syndromes combine more than one mechanism. The cannabinoid response varies by mechanism. A 1:1 CBD:THC ratio that works well for arthritis can be the wrong protocol for fibromyalgia. A THC-dominant formulation that helps neuropathic pain can produce minimal benefit in nociplastic pain. Treating chronic pain as a single category is what produces the inconsistent clinical results that have made some pain specialists skeptical of cannabis. The underlying evidence base is strong; the clinical inconsistency comes from protocol mismatch, not from cannabinoid effects being unreliable.
This page is the umbrella for the EdibleRank Pain cluster. It covers the evidence base honestly, the four mechanism categories and the cannabinoid response each one supports, the realities of using cannabis as an opioid-sparing adjunct rather than a complete substitute, and the prescription-drug interactions that matter for the polypharmacy patient population. Specific pain subtypes (fibromyalgia, migraine, neuropathic pain, arthritis, lower back pain, endometriosis pain, menstrual cramps, post-surgical pain) get their own dedicated pages over the coming weeks, with protocols tuned to each mechanism profile.
What does the research actually show about cannabis for chronic pain?
The clinical evidence on cannabis for chronic pain is the strongest in the cannabis-medicine field. The Whiting 2015 JAMA meta-analysis pooled 28 randomized controlled trials and found that cannabinoid treatment produced roughly a 30 percent reduction in pain compared to placebo, a clinically meaningful effect size on par with many first-line analgesics. The Mücke 2018 Cochrane Review focused on neuropathic pain and found a smaller but still meaningful effect, with the most consistent benefit for nerve-pain conditions like diabetic neuropathy and post-herpetic neuralgia. The Nugent 2017 Annals of Internal Medicine systematic review, funded by the US Department of Veterans Affairs, reached similar conclusions and added population-level analysis showing reduced opioid prescriptions in states with medical cannabis access.
The 2017 NASEM report is the most authoritative single document in the field. Tasked by the federal government with synthesizing the cannabis-and-health literature across all indications, the committee concluded that the evidence for chronic pain in adults rose to the "conclusive or substantial" tier, the highest evidence category they used. The only other indications that reached this tier in the report were chemotherapy-induced nausea and spasticity in multiple sclerosis. For most other conditions the report reviewed (anxiety, depression, sleep, PTSD), the evidence tier was "moderate" or "limited." Chronic pain is qualitatively different.
The 2025 AHRQ Living Systematic Review, which updates continuously, has continued to find moderate-strength evidence for cannabis in chronic pain broadly, with stronger evidence in specific subtypes (neuropathic pain, fibromyalgia) and weaker evidence in others (acute post-surgical pain, headache). The Living Review format matters because the field is still moving. New trials report regularly, and the synthesis updates as new data arrives. Patients reading this page in 2027 will likely have access to additional trial evidence beyond what is summarized here.
Where the evidence is weaker is in dose-response data and head-to-head comparisons between formulations. The published trials used a wide range of cannabinoid mixes, doses, and routes of administration. What worked best in any specific trial is less clear than that cannabinoids worked. The protocols on this page and the subtype pages are reasoned from the available trial evidence combined with mechanism considerations, not from a single definitive dosing study.
What the evidence does not support is the dispensary marketing position that high-THC products produce better pain relief than moderate-dose products. Across the trial literature, the dose-response curve flattens past 20 to 30mg total daily THC, with side effects continuing to rise. The 50mg gummy is not a stronger version of the trial-supported intervention. It is a different product, and for most chronic pain patients, the difference makes outcomes worse rather than better.
What are the four mechanism categories that matter?
Pain medicine recognizes four main mechanism categories, and the cannabinoid response varies meaningfully across them.
Nociceptive pain arises from actual or threatened tissue damage. Arthritis, lower back pain from disc or joint pathology, post-surgical pain, and most acute injury pain fall in this category. The peripheral nociceptors detect noxious stimuli (mechanical, thermal, inflammatory), and the signal travels through standard pain pathways to the central nervous system. For nociceptive pain, the cannabinoid protocol that fits the evidence is 1:1 CBD:THC at modest doses, typically 5 to 10mg of each. CBD's anti-inflammatory effects address the upstream tissue irritation. THC at low doses modulates pain perception centrally without producing the impairment that higher doses produce. This is the protocol the EdibleRank pain ranking is built around.
Neuropathic pain arises from damage or dysfunction in the nervous system itself, rather than from peripheral tissue damage. Diabetic peripheral neuropathy, post-herpetic neuralgia (shingles aftermath), chemotherapy-induced peripheral neuropathy, and pain after spinal cord injury are typical examples. The pain quality is often described as burning, electric, or shooting, and standard NSAIDs are usually ineffective. The Mücke 2018 Cochrane Review found small but meaningful effects for cannabis in neuropathic pain. The protocol leans more THC-dominant (10 to 15mg THC with 5 to 10mg CBD adjunct), because THC's action at CB1 receptors in the central nervous system appears to be the active mechanism for this pain type.
Nociplastic pain is the newest category and the most relevant to cannabis. Recognized by the International Association for the Study of Pain in 2017, nociplastic pain arises from altered nociception without clear evidence of tissue damage or nerve dysfunction. Fibromyalgia is the canonical example. Some forms of irritable bowel syndrome pain fall here. Central sensitization, where the central nervous system amplifies pain signals beyond what peripheral input would predict, is the underlying mechanism. Ethan Russo's 2008 endocannabinoid deficiency hypothesis targets this category directly: the idea that fibromyalgia, migraine, and IBS share a deficiency in endocannabinoid tone, which would explain why cannabis produces benefit in these conditions when other analgesics often do not. The hypothesis is not yet proven, but the mechanism story is compelling enough that several research groups are investigating it directly.
Mixed pain syndromes combine more than one mechanism. Migraine has nociceptive components (vascular and meningeal pain) plus nociplastic components (central sensitization in chronic migraine). Endometriosis combines visceral nociceptive pain, neuropathic pain from nerve involvement, and nociplastic central sensitization in chronic cases. Complex regional pain syndrome includes all three. Mixed pain syndromes are common, and the cannabinoid protocol depends on the dominant mechanism. The subtype pages in this cluster address the specific mechanism profile of each condition.
How does cannabis interact with opioids and other pain medications?
The opioid-sparing question is the single most clinically important application of cannabis in chronic pain, and the population-level evidence is strong. Boehnke 2016 surveyed 244 chronic pain patients enrolled in a medical cannabis program and found a 64 percent mean reduction in opioid use after starting cannabis. The Boehnke 2019 follow-up extended this to a larger cohort with similar findings. Bradford and Bradford 2017 analyzed Medicare Part D prescription data across all US states and found that states implementing medical cannabis programs saw substantial reductions in opioid prescriptions written to Medicare enrollees, with effect sizes that translated to billions of dollars in reduced opioid prescriptions annually. The Nugent 2017 VA-funded systematic review reached compatible conclusions.
What none of this evidence supports is the position that cannabis is a complete opioid replacement. Patients on long-term opioids for severe chronic pain often need both. The honest clinical framing is that cannabis is an opioid-sparing adjunct: it reduces the opioid dose needed for adequate pain control, with downstream benefits in reduced opioid side effects, lower overdose risk, and reduced tolerance escalation. The substitution decision and the opioid taper belong with a pain management physician. Patients who attempt unilateral opioid discontinuation while starting cannabis often experience withdrawal-driven pain that the cannabis cannot offset, leading to either resumed opioid use at the prior dose or worse pain control than they started with.
Beyond opioids, three other interaction categories matter for the chronic pain population. First, CBD inhibits cytochrome P450 enzymes (particularly CYP3A4, CYP2C9, and CYP2D6), which slows the metabolism of warfarin, several anticonvulsants used for neuropathic pain (carbamazepine, phenytoin), and some antidepressants used for pain (amitriptyline, duloxetine at high doses). The blood levels of these medications can rise meaningfully when CBD is added, sometimes into toxic ranges. The interaction is most significant at CBD doses above 100mg daily; the protocols on this page stay well below that threshold, but patients on these medications should still check with the prescriber before adding cannabis.
Second, combined sedation. Opioids, benzodiazepines, gabapentinoids (gabapentin, pregabalin), and muscle relaxants (cyclobenzaprine, methocarbamol, baclofen) all produce sedation. THC adds to this. The combined sedation can be substantial, and fall risk rises in older patients. The protocols on this page lean modest on THC for this reason, with maximum total daily doses around 20 to 30mg rather than the 50mg single-dose products some dispensaries sell.
Third, serotonergic interactions. THC combined with serotonergic medications (SSRIs, SNRIs, some opioids like tramadol, triptans for migraine) has rare but documented reports of mood alteration and dissociation. The mechanism is not fully understood. This is not a common interaction and most patients on antidepressants tolerate cannabis without issue, but it is worth knowing about for patients taking duloxetine or venlafaxine for chronic pain.
What is the protocol for chronic pain at the umbrella level?
For most chronic pain patients without a clear mechanism diagnosis, the starting protocol is 2.5 to 5mg of THC paired with 5 to 10mg of CBD, taken 60 to 90 minutes before pain typically intensifies. For many patients this is morning and evening, occasionally with a third midday dose during flares. The 1:1 CBD:THC ratio at modest doses fits the nociceptive and mixed-mechanism populations that make up the bulk of chronic pain patients. The CBD provides anti-inflammatory and anti-anxiety effects without sedation. The modest THC dose modulates pain perception without impairment for most patients.
Titrate over two to three weeks based on pain reduction and side effects. Most chronic pain patients who respond do so at total daily doses of 10 to 20mg THC split across two or three doses. The Whiting meta-analysis pooled trials at various dose ranges and found that moderate doses consistently outperformed high doses. The side-effect curve worsens past 30mg total daily THC without proportional benefit. Higher than 30mg daily is rarely the right answer at the umbrella level, though some specific subtypes (severe neuropathic pain) may justify pushing higher under clinical supervision.
For patients whose pain has a clear mechanism profile, the subtype pages in this cluster provide more specific protocols. The umbrella protocol above is the right starting point if you do not yet know which mechanism category fits your pain. After two to three weeks at the starting protocol, the response or lack thereof informs which subtype page to read next. Strong response with modest CBD-leaning doses suggests nociceptive pain. Partial response that improves with higher THC suggests neuropathic. Response that is more consistent than the modest dose would predict, particularly in fibromyalgia, IBS, or migraine populations, suggests nociplastic pain and the Russo endocannabinoid deficiency model.
What subtypes does the EdibleRank Pain cluster cover?
This umbrella opens the EdibleRank Pain cluster. Over the coming months, dedicated pages cover the major chronic pain subtypes, each with mechanism-specific protocols and condition-specific evidence:
Fibromyalgia. The canonical nociplastic pain condition. The Russo endocannabinoid deficiency hypothesis fits here. Most consistent reports of benefit at modest cannabinoid doses, with the mechanism story more developed than for most pain conditions. Cluster page in mid-June.
Migraine. A mixed pain syndrome with both nociceptive and nociplastic components. Cannabis for migraine has a small but specific evidence base, and the cannabinoid profile differs between acute treatment (during attack) and prophylactic use (preventing attacks). Cluster page in late June.
Neuropathic pain. The pain category with the most rigorous individual evidence base (Mücke 2018 Cochrane). Higher THC dominance fits the mechanism. Cluster page in early July.
Arthritis. Nociceptive inflammatory pain. The 1:1 CBD:THC protocol that the umbrella recommends fits well, with CBD's anti-inflammatory effects adding meaningfully. Cluster page in mid-July.
Lower back pain. Most often nociceptive (disc, facet joint, muscular), sometimes with neuropathic components (radiculopathy). The most common chronic pain presentation in primary care. Cluster page in late July.
Endometriosis pain. A mixed-mechanism condition with visceral, neuropathic, and nociplastic components. The cannabinoid response and the protocols differ from general pelvic pain. Cluster page in late June.
Menstrual cramps. Primarily nociceptive (prostaglandin-mediated inflammation) but with central sensitization in chronic dysmenorrhea. Cluster page in late July.
Post-surgical pain. Acute nociceptive pain transitioning to chronic in a subset of patients. The cannabinoid evidence here is weaker, and the role is more often opioid-sparing adjunct than primary analgesic. Cluster page in early August.
Each subtype page treats the condition as its own clinical entity with its own evidence base, its own mechanism profile, and its own protocol tuning. The reader who works through more than one subtype will notice the pattern: cannabis is not a single answer to chronic pain. It is a class of tools that fit different pain mechanisms differently, and clinical effectiveness depends on matching the cannabinoid choice to the underlying biology.